Skip to main content

Paradigm Genetics Licenses Rosetta Resolver Gene Expression System

NEW YORK, Dec 29 – Paradigm genetics has licensed the Rosetta Resolver gene expression analysis system from Rosetta Inpharmatics and Agilent Technologies, the companies announced Friday.

The companies did not disclose the financial terms of the agreement. Agilent has been the exclusive distributor of the Rosetta Resolver, a bioinformatics gene expression analysis system that can be used with a variety of microarrays, since December 1999.

Rosetta has previously licensed the Resolver, which it launched in its newest version October 3, to Glaxo Wellcome and the Harvard Center for Genomics Research. Rosetta also recently opened a new gene expression profiling facility in Bothell, Wash.

The Scan

WHO OKs Emergency Use of Sinopharm Vaccine

The World Health Organization has granted emergency approval for Sinopharm's SARS-CoV-2 vaccine, the Guardian reports.

Scientific Integrity Panel to Meet

According to the Associated Press, a new US scientific integrity panel is to meet later this week.

Trying in the Eye

NPR reports that a study of Editas Medicine's CRISPR therapy for Leber congenital amaurosis has begun.

PLOS Papers on Cerebellum Epigenetics, Copy Number Signature Tool, Acute Lung Injury Networks

In PLOS this week: epigenetics analysis of brain tissue, bioinformatics tool to find copy number signatures in cancer, and more.